Teza Capital Management’s Charles River Laboratories CRL Stock Holding History

Teza Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,847	Closed	-$710K	–	429
2024 Q4	$710K	Buy	+3,847	New	+$741K	0.11%	236
2024 Q3	–	Sell	-4,849	Closed	-$1M	–	623
2024 Q2	$1M	Buy	+4,849	New	+$1.1M	0.12%	240
2019 Q1	–	Sell	-10,077	Closed	-$1.14M	–	318
2018 Q4	$1.14M	Buy	10,077 +917	+10%	+$115K	0.43%	69
2018 Q3	$1.23M	Buy	9,160 +1,753	+24%	+$216K	0.28%	133
2018 Q2	$832K	Buy	+7,407	New	+$801K	0.12%	301

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Teza Capital Management's CRL Position: Q1 2025 in Review

Teza Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 3,847 shares — an estimated $710K sold.

Teza Capital Management first reported a position in CRL in Q2 2018 and held it in 5 quarters. The position peaked at $1.23M in Q3 2018. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Teza Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Teza Capital Management sold 3,847 Charles River Laboratories shares in Q1 2025, an estimated $710K.
Teza Capital Management first reported a position in Charles River Laboratories in Q2 2018 and held it in 5 quarters.
Teza Capital Management's Charles River Laboratories position peaked at $1.23M in Q3 2018.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Teza Capital Management's 13F filing for Q1 2025, filed 15 May 2025.